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 Some time ago the transplantation   com-
munity moved past the notion that 
rejection is mediated exclusively via 
direct invasion of activated immune cells, 
that is, cytotoxic T lymphocytes in the 
allograft . Instead, acute cellular rejection 
is now known to oft en be accompanied 
by antibody-mediated phenomena, 
although occasionally antibody- mediated 
rejection can occur in the absence of 
acute cellular rejection. Th e antibodies 
involved in these phenomena were ini-
tially identifi ed as targeting donor human 
leukocyte antigen (HLA ) and causing 
damage by activating complement. Th is 
discovery resulted in techniques to better 
diagnose and characterize these anti-
body-mediated processes — for example, 
identifi cation of donor-specifi c antibod-
ies and titer quantifi cation in recipient 
sera. As well as staining of biopsy tissue 
for C4d . 
 Recently, it has become increasingly 
clear that antibodies not directed against 
donor HLA and not causing  complement-
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 Antibodies against non-HLA targets are increasingly recognized in the 
context of transplant rejection. However, their specific role remains 
largely elusive, as evidence exists supporting both their occurrence as 
an epiphenomenon and their actual pathogenicity in the rejection 
process. Sutherland  et al. describe protein kinase C  as a novel, non-HLA 
antigenic target in the setting of graft rejection. 
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mediated lysis of target tissues may also 
play roles in the pathogenesis of acute and 
chronic graft  damage. 1 Sutherland  et al. 2 
(this issue) present work that elaborates 
on this concept. Using protein microarray 
technology, they screened 15 pediatric 
kidney transplant recipients with acute 
cellular rejection (several with concomi-
tant evidence of antibody-mediated phe-
nomena, that is, positive C4d staining, 
detectable donor-specifi c antibodies, or 
antibodies directed against HLA that was 
not donor-specifi c) for  de novo antibodies 
against 5056 potentially antigenic protein 
targets. Th ey found  de novo antibody for-
mation against 229 non-HLA proteins, 
with antibodies against 36 of these targets 
detectable in more than one of the 
patients with rejection. Of all observed 
antibody responses, the strongest 
occurred against protein kinase C  
(PKC  ) in three individuals. While C4d 
staining was negative in the biopsies of 
these patients, they had particularly recal-
citrant clinical courses, and two of them 
lost their transplants within 2 years. In 
contrast, none of the 12 other patients 
with rejection but without a strong anti-
PKC  response experienced graft loss 
during follow-up. 
 Th e authors interpret their fi ndings 
with appropriate caution given their 
relatively small patient-sample size and 
the retrospective structure of their 
study. Although they consider detecta-
ble anti-PKC  to be a likely marker for 
rejection associated with poor graft 
 survival, they do not believe that it is a 
pathogenic antibody. This notion of 
anti-PKC  as a bystander is at least in 
part based on the authors ’ inability to 
detect C4d in the transplant biopsies of 
the rejection patients with a strong anti-
PKC   response. Accordingly, they 
hypothesize that, in these patients, 
severe renal injury and cell death led to 
PKC  exposure and subsequent anti-
body formation ( Figure 1 , top). 
 Could anti-PKC  be a novel mediator 
of an unusually aggressive subtype of 
rejection? Th is would be possible, if anti-
PKC  antibodies were activating simi-
larly to those against angiotensin II 
receptors described by Dragun  et al. 3 
PKC  plays critical roles in immune sig-
naling pathways, 4,5 and its excessive 
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antibodies. Lastly, it would be interesting 
to elucidate why some individuals gener-
ate signifi cant titers of anti-PKC  anti-
bodies during acute rejection episodes 
whereas others do not. 
 Th e fascinating observations made by 
Sutherland  et al. 2 with their innovative 
protein microarray approach provide new 
avenues of investigation that could lead to 
a better understanding of the role of non-
HLA antibodies and their targets in graft  
rejection. Currently, we simply do not 
know yet whether these antibodies are 
conspicuous bystanders or pathogenic 
suspects in the immune responses 
involved in graft  rejection. 
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 activation in recipient lymphocytes could 
thus contribute signifi cantly to rejection. 
Along these lines, PKC  has been shown 
to target to lipid raft s in macrophages 
stimulated via Toll-like receptor 2, 6 sug-
gesting that the kinase could be more 
exposed as a target for antibodies in acti-
vated immune cells ( Figure 1 , bottom). 
However, evidence is lacking to support 
this concept in lymphocytes involved in 
allograft  rejection. 
 Further, both processes could occur 
sequentially: Exposure of donor PKC  in 
kidney tissue damaged by rejection could 
fi rst lead to the generation of antibodies 
against the kinase. Subsequently, those 
antibodies could bind to and activate 
recipient PKC  aft er its translocation to 
lipid raft s on the surface of immune cells 
participating in the rejection process. 
Th is activation could thus amplify the 
intensity of the rejection, explaining the 
particularly poor outcomes seen by Suth-
erland  et al. 2 in patients with anti-PKC  . 
 Clearly, future studies are needed to 
better understand the exact role of PKC  
and the antibodies against it (and other 
targets identifi ed by the authors) in graft  
rejection. Such studies should clarify 
whether these antibodies are auto- or 
alloantibodies, that is, whether they are 
directed against the donor or recipient 
PKC  (or both); whether they indeed 
activate the pathways; and whether they 
can modulate immune responses in 
manners not involving complement acti-
vation, as suggested by Sumitran-
Holgersson 1 for other non-HLA 
 Figure 1  |  Possible roles for PKC  (yellow triangles) and antibodies against it (blue Ys) in 
kidney transplant rejection. Top: Donor PKC  in the graft could become exposed as an antigenic 
target if inflammatory events during a rejection episode significantly impair tissue integrity. 
Bottom: Recipient PKC  , after translocating into lipid rafts (curved blue disks ) during immune 
activation, becomes accessible to potentially activating anti-PKC  antibodies, providing a possible 
mechanism for amplification of the rejection response. 
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